the $10 mill IP they got made the cash look like plus 5 mill for two q's... so the underlying cash really stayed about MINUS $2.5 mill a Q
but it was slowly improving, the cash burn; but the MINUS 3.7 mill in the last Q was a wowser, out of the blue for me
so THIS YR CASH FLOW q1 was minus 2.6 mill and q2 was minus 3.7 mill
they just cannot burn cash at such rates
what confuses me is the services side was on the up 18 months ago, then it was LOW (on purpose they said) because they put their staff/resources into the FebriDx ramp up. So the cash burn (and low revenue) of Q1FY24 and Q2FY24 was planned; that is what they said; yet the underlying cash burn remains at minus 2.5 mill, so it is like there ramp up efforts of Q1FY24 and Q2FY24 yielded ZILCH over the next four quarters; and the services do not seem to have fully got back to speed
so we are like a rubber band, coiled to launch into wonderousness... or to break
I have always said the Q I am interested is this Jan/Feb/Mar Q where we have the $42 rebate in the USA and the sick season was upon us in USA... but then we learn the Drs in the USA cant be bothered using FebriDx as 'too much paperwork' to get the rebate; so we have a FREE product that combats AMR... and it is not selling (as far as I can see)
Now if FebriDx is a dud, sobeit; the company is more than that, but they seem to have lost focus; they are doing lots of projects that all do not make any money... it is really, really odd
Add to My Watchlist
What is My Watchlist?
